You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. The Alleged CELLECTRA Device Manufacturing Deficiencies The biotechnology sector relies heavily on medical ...
What are the allegations? Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device According to the complaint, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Inovio's handheld Cellectra device is essential to ...
PLYMOUTH MEETING, Pa., June 23, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has received $71 million funding from the U.S. Department of Defense (DoD) to support the large-scale ...
Last week the United States Food and Drug Administration (FDA) authorized the biotechnology company Inovio to move forward with clinical trials in the United States to test their DNA-based plasmid ...
PLYMOUTH MEETING, Pa., Nov. 16, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from ...
PLYMOUTH MEETING, Pa., Dec. 7, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from ...
Inovio Pharmaceuticals, Inc. INO announced today the peer-reviewed publication of results from two phase I trials (HVTN 070 and HVTN 080) of its PENNVAX^®-B preventive HIV DNA vaccine delivered with a ...
SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (INO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results